Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …

The neonatal Fc receptor for IgG (FcRn) has been well characterized in the transfer of
passive humoral immunity from a mother to her fetus. In addition, throughout life, FcRn …

The development of therapeutic antibodies has evolved over the past decade into a
mainstay of therapeutic options for patients with autoimmune and inflammatory diseases …

With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …

Monoclonal antibodies (mAbs) have been used in the treatment of various diseases for over
20 years and combine high specificity with generally low toxicity. Their pharmacokinetic …

Antibodies constitute the most rapidly growing class of human therapeutics and the second
largest class of drugs after vaccines. The generation of potent antibody therapeutics, which I …

Immunoconjugates—monoclonal antibodies (mAbs) coupled to highly toxic agents,
including radioisotopes and toxic drugs (ineffective when administered systemically alone) …

Antibodies have proven to be effective agents in cancer imaging and therapy. One of the
major challenges still facing the field is the heterogeneous distribution of these agents in …

The direct or indirect targeting of antibody Fc receptors (FcRs) presents unique opportunities
and interesting challenges for the treatment of inflammatory diseases, cancer and infection …

Human IgG3 displays the strongest effector functions of all IgG subclasses but has a short
half-life for unresolved reasons. Here we show that IgG3 binds to IgG-salvage receptor …